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Abstract
Background: Spontaneous Regression/Complete Resistant (SR/CR) mice are resistant to cancer through
a mechanism that is mediated entirely by leukocytes of innate immunity. Transfer of leukocytes from SR/
CR mice can confer cancer resistance in wild-type (WT) recipients in both preventative and therapeutic
settings. In the current studies, we investigated factors that may impact the efficacy and functionality of SR/
CR donor leukocytes in recipients.
Results: In sex-mismatched transfers, functionality of female donor leukocytes was not affected in male
recipients. In contrast, male donor leukocytes were greatly affected in the female recipients. In MHC-
mismatches, recipients of different MHC backgrounds, or mice of different strains, showed a greater
negative impact on donor leukocytes than sex-mismatches. The negative effects of sex-mismatch and
MHC-mismatch on donor leukocytes were additive. Old donor leukocytes performed worse than young
donor leukocytes in all settings including in young recipients. Young recipients were not able to revive the
declining function of old donor leukocytes. However, the function of young donor leukocytes declined
gradually in old recipients, suggesting that an aged environment may contain factors that are deleterious
to cellular functions. The irradiation of donor leukocytes prior to transfers had a profound suppressive
effect on donor leukocyte functions, possibly as a result of impaired transcription. The cryopreserving of
donor leukocytes in liquid nitrogen had no apparent effect on donor leukocyte functions, except for a small
loss of cell number after revival from freezing.
Conclusion: Despite the functional suppression of donor leukocytes in sex- and MHC-mismatched
recipients, as well as old recipients, there was a therapeutic time period during the initial few weeks during
which donor leukocytes were functional before their eventual rejection or functional decline. The eventual
rejection of donor leukocytes will likely prevent donor leukocyte engraftment which would help minimize
the risk of transfusion-associated graft-versus-host disease. Therefore, using leukocytes from healthy
donors with high anti-cancer activity may be a feasible therapeutic concept for treating malignant diseases.
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Background
Spontaneous regression/complete resistant (SR/CR) mice
are a line of cancer-resistant mice that are capable of resist-
ing large doses of transplanted lethal cancer cells [1-3].
The basis for this powerful resistance to cancer cells is leu-
kocytes that are capable of detecting, infiltrating, and kill-
ing cancer cells within a few hours of exposure [1]. The
major component of this anti-cancer response resides in
granulocyte, monocyte, and natural killer cell fractions
that constitute innate cellular immunity [1,2]. The adop-
tive transfer of donor leukocytes from SR/CR mice can
confer protection against future exposures to cancer cells,
as well as the elimination of established malignancies
without any further manipulation in cancer-sensitive
wild-type (WT) recipient mice [2].
These prior studies suggest that it may be possible to
develop a similar leukocyte transfer platform for humans
if we can identify humans with anti-cancer activity similar
to the SR/CR mice to serve as leukocyte donors. However,
the prior adoptive transfers of donor leukocytes in these
mice were considerably different from what would be nec-
essary in human cancer patients. The leukocyte transfers
in mice were done in MHC-matched and relatively young
recipients [2]. In the potential human setting, the circum-
stance could be vastly different.
First, it is not known how much of an effect a sex mis-
match would have on the donor leukocytes. It is possible
for a donor leukocyte treatment to involve donors that are
a different sex than the recipient. While female donor leu-
kocytes in a male recipient are not expected to cause sub-
stantial problems, it is reasonable to expect some issues
with male donor leukocytes in female recipients because
of the existence of unique proteins associated with y-chro-
mosome gene expression [4]. However, it is unclear how
much of an impact this incompatibility would have on
the functionality of male donor leukocytes, and if this
mismatch is enough to render the donor leukocytes inef-
fective in the recipients.
Second, in the human setting, a long-term engraftment of
donor leukocytes, especially donor T lymphocytes, should
be avoided in order to minimize the possibility of transfu-
sion-associated graft-versus-host diseases (TA-GVHD) [5].
The long-term engraftment of donor leukocytes in immu-
nocompetent individuals is usually caused by an incom-
plete but near match of human lymphocyte antigens
(HLA) between the donor leukocytes and the recipients,
such as donor leukocytes from blood relatives [6,7]. One
way to help avoid long-term engraftment is by transferring
donor leukocytes into immunocompetent recipients that
have been selected based on a complete HLA mismatch.
The complete HLA-mismatch between donors and recipi-
ents should cause the donor leukocytes to be rejected in
several weeks to several months. Our prior mouse transfer
experiments have shown that the donor leukocytes can
work in a rapid manner over the course of several days, or
2-3 weeks in the MHC-matched background. In the set-
ting of a human leukocyte transfer, a complete HLA-mis-
matched scenario would minimize the risk for TA-GVHD
in an immunocompetent individual due to the timely
rejection of the donor cells before the occurrence of TA-
GVHD. However, it is unknown whether there is an initial
therapeutic window before the donor leukocytes are even-
tually rejected due to the HLA-mismatch, in which the
donor leukocytes may still offer an effective time period in
which the donor leukocytes are functional.
Third, the transfers in the prior studies were done prima-
rily with young mice as the recipients and donors [2]. The
scenario in the human setting would most likely be much
more complicated. Since there is extensive immune dys-
function that occurs as one ages [8,9], it is assumed that
younger individuals would have better immune cell func-
tion and, therefore, make better donors. Even if younger
individuals were used as donors, the leukocytes would be
transferred into cancer patients who consist mainly of an
older population [10]. Based on prior results, it is thought
that the aged cellular environment may contain circulat-
ing factors that are inhibitory to the functions of younger
cells [11]. However, it is currently unknown how much of
an impact the older recipient environment would have on
the functionality of younger donor leukocytes.
In this paper, we describe the results of studies that deter-
mine the impact of sex, MHC, and age on the therapeutic
effects of SR/CR donor leukocytes in a lethal cancer
model.
Results and discussion
Transferred anti-cancer activity in MHC-and sex-
mismatched recipients
To determine the impact of different recipient MHC and
sex backgrounds on transferred anti-cancer activity, we
performed a set of experiments where the mice were
intentionally mismatched for strain and sex. For the sex-
mismatch, SR/CR BALB/c male donor leukocytes were
transferred into WT BALB/c female recipients, or SR/CR
BALB/c female donor leukocytes were transferred into WT
BALB/c males. For the MHC-mismatch, SR/CR BALB/c
female donor leukocytes were transferred into WT C57BL/
6 female recipients, or SR/CR BALB/c male donor leuko-
cytes were transferred into WT C57BL/6 male recipients.
For the sex- and MHC- double mismatch, SR/CR BALB/c
male donor leukocytes were transferred into female WT
C57BL/6 recipients, or SR/CR BALB/c female donor leu-
kocytes were transferred into WT C57BL/6 males. All WT
recipient mice were then challenged with 1 × 106 S180
cells, 24 hours after the adoptive transfer, to evaluate theBMC Cancer 2009, 9:328 http://www.biomedcentral.com/1471-2407/9/328
Page 3 of 8
(page number not for citation purposes)
anticancer activity of the transferred leukocytes. The sur-
viving mice were then challenged with 1 × 106 S180 two
more times with 5-6 week intervals between the injec-
tions. As expected, the sex- and MHC-matched controls
showed 100% overall survival after all three S180 chal-
lenges (Figure 1). The sex-mismatch mice resulted in an
overall survival of 83% (Figure 1) after three S180 chal-
lenges. The MHC-mismatch resulted in a reduction of
overall survival (58%) which was maintained for each of
the subsequent tumor challenges (Figure 1). When the
recipients were mismatched for both MHC and sex, the
overall survival dropped to approximately 42%, but
remained unchanged after the first tumor challenge. Inter-
estingly, when the recipients were evaluated by sex (Figure
2), the female recipients displayed a lower survival in all
mismatched groups tested. When the transfers were mis-
matched for sex, 100% survival was observed in the male
recipients with only 67% survival in the female recipients
(Figure 2). When the recipients were MHC-mismatched,
the male recipients had 83% survival while the females
only had 33% survival (Figure 2). Finally, in the double-
mismatch for sex and MHC, male recipients had a higher
survival percentage (67%) when compared to the female
recipients (17%) (Figure 2). All of the failed adoptive
transfers were observed during the first challenge with
S180 since the percent survival remained unchanged
throughout the second and third challenges for all groups
evaluated (Figure 1).
Out of the 36 mice that received mismatched adoptive
transfers, 61% of the mice remained healthy with no signs
of malignancy or GVHD development (Figure 3A, Col-
umn W). Following the first challenge with S180 cells,
31% of the recipients developed ascites (Figure 3A, Col-
umn X) which suggests that the donor leukocytes were
rejected in the recipient. Approximately 5.5% of the mis-
matched mice died of unknown causes while approxi-
mately 2.5% of the mismatched mice (n = 1) displayed fur
Functionality of donor leukocytes in mismatched recipients Figure 1
Functionality of donor leukocytes in mismatched 
recipients. The pooled donor leukocytes were evenly given 
to the recipients intraperitoneally (IP). After transfers of 
donor leukocytes, recipient mice were challenged with 1 × 
106 S180 cells IP. The percent survival of the recipient mice 
was presented to indicate the functionality of the transferred 
donor leukocytes after the first challenge (left bars, 1 day 
after the transfer), second challenge (middle bars, 6 weeks 
after the transfer) and third challenge (right bars, 12 weeks 
after the transfer). All recipient mice were WT mice that 
were sensitive to S180 challenges. For the matched controls, 
6 male BALB/c recipients were given male BALB/c SR/CR 
donor leukocytes and 6 female BALB/c recipients were given 
female BALB/c SR/CR donor leukocytes. For the sex mis-
match, 6 female BALB/c recipients were given male BALB/c 
SR/CR donor leukocytes; 6 male BALB/c recipients were 
given female BALB/c SR/CR donor leukocytes. For the MHC 
mismatch, 6 male C57BL/6 mice were given male BALB/c SR/
CR leukocytes and 6 female C57BL/6 mice were given female 
BALB/c SR/CR leukocytes. For the sex and MHC double mis-
match, 6 female C57BL/6 mice were given male BALB/c SR/
CR leukocytes and 6 male C57BL/6 mice were given female 
BALB/c SR/CR leukocytes. The percent survival for each of 
the adoptive transfers remains unchanged after each subse-
quent S180 challenge. The overall survival for each experi-
mental group was as follows: matched is 100%, sex mismatch 
is 83%, MHC mismatch is 58%, and MHC + sex mismatch is 
42%.
Functionality of donor leukocytes in recipients of different  sexes Figure 2
Functionality of donor leukocytes in recipients of dif-
ferent sexes. These are the same experimental conditions 
as those described in Figure 1. The left bars of each column 
are survival percentages of male recipient mice and right bars 
are those of female recipient mice after the completion of all 
three S180 IP challenges. The female recipients display a 
lower survival in all mismatched groups. The percent survival 
for each group is as follows: male 100% versus female 67% 
for the sex-mismatch, male 83% versus female 33% for MHC-
mismatch, and male 67% versus female 17% for sex- and 
MHC-mismatch.BMC Cancer 2009, 9:328 http://www.biomedcentral.com/1471-2407/9/328
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discoloration which is suggestive for GVHD (Figure 3A,
Column Z, Figure 3B, C). This one mouse had a discolor-
ation of fur (Figure 3B) that appeared approximately 14
days post-adoptive transfers. Upon histological evalua-
tion, post inflammatory pigment incontinence was
observed (Figure 3C). The black arrows point to areas with
normal appearing pigmentation while the green arrows
point to areas of pigment incontinence, in which the pig-
ment was localized in macrophages at the periphery of the
follicles. This observation suggests a prior inflammatory
response that resolved prior to the end of the study. In the
human setting, transfusion associated GVHD is a rare
complication that is associated with fever, rash, abdomi-
nal pain, vomiting and diarrhea and is usually fatal [5,6].
These symptoms were not found in the treated mice; how-
ever the fur discoloration is suggestive of a GVHD reac-
tion.
Transferred anti-cancer activity in recipients of different 
ages
Since most cancers occur in an aged population [10], we
wanted to evaluate what impact this could have on adop-
tively transferred leukocytes. Leukocytes were transferred
from young (4.75 ± 0.5 months) or old (22.88 ± 3.54
months) SR/CR C57BL/6 donors to young (3 months) or
old (24 months) C57BL/6 WT mice, with sex and MHC
are both matched. The recipient mice were then initially
challenged with 1 × 106 S180 24 hours after the adoptive
transfer, followed by three subsequent S180 injections
with 5-6 week intervals. As seen in the survival curve (Fig-
ure 4A), the control group (young donor leukocytes to
young recipients) resulted in the highest overall survival
percentage among the four groups. When an aged mouse
was used as either the donor or the recipient, the survival
was drastically reduced in all three groups, either immedi-
ately or over time following the adoptive transfer (Figure
4A). When the survival was evaluated after each S180
injection, three of the four groups (young donor to young
recipient, old donor to old recipient, and old donor to
young recipient) showed minimal changes after the initial
S180 challenge (Figure 4B). In contrast to the other three
groups, when young cells were transferred to an old envi-
ronment, the recipients initially displayed a high percent
survival, but then showed a continual decline after each
subsequent challenge with S180 presumably due to the
impact of the aged host environment on the donor leuko-
cytes (Figure 4B).
Effect of irradiation on the function of transferred 
leukocytes
The irradiation of cells can be used to help minimize the
risk of GVHD in adoptive immunotherapy settings [12].
Side effects associated with the adoptive transfers Figure 3
Side effects associated with the adoptive transfers. A) Incidental rates as a result of the leukocyte transfer. "W" (61%) 
refers to successful transfer of anticancer activity and protection of the recipient mice from subsequent challenges with S180. 
"X" (31%) refers to the animals that developed S180-induced ascites presumably due to the rejection of donor leukocytes by 
the recipients. "Y" (5.5%) refers to the deaths of recipient mice after the transfer of donor leukocytes due to unknown rea-
sons, but not due to development of ascites. "Z" (2.5%) refers to an incident of fur discoloration post-adoptive transfer poten-
tially representing graft-versus-host disease. B) An image of fur discoloration as a result of donor leukocyte transfers. C) Skin 
histology under discolored fur indicates post inflammatory pigment incontinence. The black arrows point to areas with normal 
appearing pigmentation while the green arrows point to the areas of pigment incontinence in which the pigment localized in 
macrophages at the periphery of the follicles.BMC Cancer 2009, 9:328 http://www.biomedcentral.com/1471-2407/9/328
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The irradiation irreversibly damages the DNA of the leu-
kocytes, preventing their cell division without killing the
cells. However, it is unclear if this process may have an
immediate affect on the anticancer killing activity of the
leukocytes. To evaluate this in our model, leukocytes of
the spleen were harvested from C57BL/6 SR/CR mice,
pooled, and then split into two groups. One group was
irradiated (25Gy), while the other served as the nonirradi-
ated control group. Each group was transferred to C57BL/
6 WT mice and challenged 24 hours later with 1 ×
106S180. The nonirradiated controls resulted in 100%
survival, while the irradiated group displayed a reduction
to only 38% survival (Figure 5). Overall, irradiation nega-
tively impacted, but did not abolish the cancer killing
activity of the SR/CR leukocytes.
Effect of cryopreservation on the function of donor 
leukocytes
Cryopreservation is a common practice for storing cells
[13,14]. Most of the time the viability of stored cells is
minimally affected by freezing and thawing, it is not clear
whether a specific functionality, such as the anticancer
activity of SR/CR donor leukocytes, can be affected by cry-
opreservation. Leukocytes were harvested from SR/CR
donor mice, pooled and divided into two groups. One
was given directly to WT mice as a non-frozen control,
while the other cells were frozen for approximately 30
days. Then, these cells were thawed and given to another
group of WT mice. There were 6 mice used for the post-
cryopreservation due to the loss of a tube of cells during
the retrieval process. By using 6 for the group, then the
number of cells given per recipient was closer to the con-
trol recipients' numbers (within 2 × 106 leukocytes). Both
groups of WT mice were challenged with 1 × 106 S180 cells
24 hours after the designated adoptive transfers. Even
with the slightly reduced number of leukocytes delivered
after cryopreservation, both groups showed identical sur-
vival (100%) after a challenge with S180 (Figure 5).
Therefore cryopreservation appeared to have no negative
impact on the cancer killing activity of the SR/CR leuko-
cytes.
Conclusion
It has long been theorized that clinically significant cancer
is caused by a defective immune system which results in a
loss of activity capable of removing cancer cells that are
Impact of leukocyte age and recipient age on donor leukocyte functionality Figure 4
Impact of leukocyte age and recipient age on donor leukocyte functionality. A) Survival curves. The ages of "young" 
C57BL/6 SR/CR donors were 4.8 ± 0.5 months and "old" donors were 22.9 ± 3.5 months. The ages of "young" C57BL/6 WT 
recipients were 2 months and "old" recipient mice were 24 months. Survival percentages of recipient mice are shown: young to 
young (Orange triangle, n = 16), young to old (Green square, n = 15), old to old (Red circle, n = 16) and old to young (Blue 
asterisk, n = 16). The adoptive transfer recipients were then challenged 1 day after the adoptive transfer, then approximately 
every 30 days thereafter for the survivors. The area to the left of the dashed line represents the impact that the age of the 
donor leukocytes has on the survival of the recipient. B) Bar chart. The same experimental conditions as described in figure 4A 
after each S180 challenge. The survival for each experimental group after the subsequent challenges was as follows: First S180 
challenge: 88% for young to young, 73% for young to old, 25% for old to young, and 25% for old to old; Second S180 challenge: 
69% for young to young, 50% for young to old, 25% for old to young, and 25% for old to old; Third S180 challenge: 69% for 
young to young, 33% for young to old, 25% for old to young, and 13% for old to old; Fourth S180 challenge: 69% for young to 
young, 13% for young to old, 25% for old to young, and 13% for old to old.BMC Cancer 2009, 9:328 http://www.biomedcentral.com/1471-2407/9/328
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continuously being generated [15]. However, adoptive
transfer of innate leukocytes from donors with a validated
high level of cancer-killing activity to cancer patients for
therapeutic purposes is a new concept. In comparison, the
major difference is that most conventional cancer immu-
notherapies try to stimulate a possibly damaged immune
system of cancer patients, whereas this new concept
attempts to supplement the damaged components of the
immune system with ones with enhanced activity. Prior
studies in SR/CR mice suggested that such a cancer surveil-
lance system can be mediated by leukocytes of the innate
immune system [1,2]. Their powerful immune system is
capable of eradicating a large number of malignant cells
that otherwise would be lethal. It may be possible to
develop similar therapeutic concepts in the human set-
ting. The studies described in this paper investigated the
factors that may have substantial impact on the efficacy of
donor leukocytes therapeutically.
Our studies indicated that male recipients had no appar-
ent inhibitory effect on the female donor leukocyte func-
tionality. On the other hand, transfers of male donor
leukocytes provoked a leukocyte rejection mechanism in
female recipients to a considerable degree. This observa-
tion is consistent with the concept that y-chromosome-
associated proteins correlate with chronic graft-versus
host disease [4] and, therefore, may provoke a time-
dependent transplant rejection in female recipients. How-
ever, even with the loss of donor leukocyte function due
to the rejection mechanism, there may still be an initial
therapeutic window during the first few days or even
weeks before the donor leukocytes are rejected. Therefore,
the transfer may still be effective in both sex-mismatched
settings at least during the first few weeks.
It is also clear that an MHC-mismatch can have a substan-
tial impact on the transferred leukocytes. This finding is
not surprising since it is well known that different MHC
molecules can provoke strong rejection mechanisms in
recipients. However, it is somewhat surprising that donor
leukocytes, regardless of whether sex-mismatch or not,
faired considerably worse in female recipients than in
male recipients in all of the mismatched settings.
Aging also had a profound inhibitory effect on the anti-
cancer activity of SR/CR leukocytes. The effects can be
divided into two parts. The first aspect is the age of the
donor leukocytes. Our data showed that old donor leuko-
cytes had drastically reduced functionality. It is interesting
to note that the age-related loss of function in the leuko-
cytes could not be restored in the young recipients. It
appeared that the functional loss in old leukocytes was
persistent and structural. However, alternatively the old
cells may have simply needed more time in the young
environment to regain function before the challenge with
the cancer cells. The second aspect is the age of recipients.
Our data showed that young leukocytes were inhibited in
old recipients. It seems that the young leukocytes were
inhibited by either the surface molecules of the host tis-
sues or by circulating diffusible host molecules in body
fluids. It has been previously shown that the circulation of
old animals contains inhibitory components that affect
young tissues and cells [11]. Our observations are consist-
ent with the theme that there are cytotoxic or inhibitory
factors in the circulation of old hosts that can abolish the
functionality of transplanted young donor leukocytes.
One of the intriguing findings was that the deleterious
effects of the host environment were not immediate. We
observed a period of time during the initial 2-3 weeks,
before the subsequent S180 challenges, in which the mice
survived the initial S180 challenge similarly to the con-
trol. This observation suggests that during the initial 2-3
weeks, the donor leukocytes could function normally
before their eventual decline.
Cryopreservation of donor leukocytes is a convenient way
of retaining cell viability for a long period of time
[13,14,16]. However, it was unclear whether the function-
ality of the stored leukocytes could be maintained. Our
studies showed that the anticancer activity of donor leu-
kocytes could be largely maintained during a period of
storage and through the processes of freezing and thaw-
ing. This observation may open up the possibility of leu-
kocyte banking from young donor leukocytes for either
autologous or allogeneic use in the future [16].
Effects of cryopreservation and irradiation on the donor leu- kocytes before transfers Figure 5
Effects of cryopreservation and irradiation on the 
donor leukocytes before transfers. The procedures of 
cryopreserving and irradiating donor leukocytes were 
described in the section of "materials and methods". After 
each adoptive transfer the groups were challenged with 1 × 
106 S180. The percent survival after the S180 challenges is 
shown. The untreated controls for both groups are 100% 
survival. The cryopreserved leukocytes also result in 100% 
survival while the leukocytes irradiated at 25 Gray results in 
38% survival.BMC Cancer 2009, 9:328 http://www.biomedcentral.com/1471-2407/9/328
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Our results also showed substantial inhibition of donor
cell functionality by irradiation. Although the anticancer
activity of donor leukocytes does not appear to require
additional cell proliferation, the effect of irradiation on
donor cell function was considerable. Irradiation at high
doses, such as 25 Gy, is known to induce DNA lesions in
treated cells [17]. While this treatment can prevent cell
proliferation, it can also shut down transcription since
intact transcripts may not be able to be generated due to
DNA damage. Our unpublished results show that SR/CR
leukocytes have a vastly different transcription profile
compared to WT leukocytes, and alteration or impairment
of gene expression as a result of radiation may cause dam-
age to transcripts required for SR/CR leukocyte killing of
cancer cells.
It was encouraging to see that there was a time period dur-
ing the initial 2-3 weeks in which the recipients' survival
was comparable to the controls again suggesting that even
in the presence of inhibitory conditions the donor leuko-
cytes were still able to function. The donor leukocytes of
the SR/CR mice displayed a meaningful anticancer func-
tionality during this initial time period before their even-
tual decline. The most likely explanation for this is that
the protective and therapeutic functions of SR/CR donor
leukocytes against cancer can be accomplished within a
few hours or days. This timeframe is well before the host's
inhibitory factors have had a chance to abolish leukocyte
function. Therefore, it is possible that donor leukocytes
may offer a new therapeutic concept in the human setting,
in which the recipients would be much older than the
donors and the donor-recipient pair would most likely be
unavoidably and intentionally mismatched. However,
even with these suboptimal conditions, donor leukocytes
may still be able to function long enough to provide a
beneficial effect.
Methods
Cell Lines and Mouse Strains
The S180 cell line was obtained from the American Type
Culture Collection (ATCC) (Manassas, VA). S180 cells
were propagated in Dulbecco's Modified Eagle Medium
(DMEM) with 10% fetal bovine serum (FBS) at 37°C in
5% carbon dioxide, or maintained by serial passage in
wild-type (WT) C57BL/6 mice as ascites tumors. C57BL/6
(H-2b) and BALB/c (H-2d) mice were purchased from The
Jackson Laboratory and Charles River, respectively. SR/CR
mice in C57BL/6 (H-2b) and BALB/c (H-2d) backgrounds
were bred at the animal resource program (ARP) facility of
Wake Forest University School of Medicine. All mice were
housed in plastic cages covered with individual air filter
tops, containing corncob bedding, allowed free access to
water and chow diet, and exposed to a 12-h fluorescent
light/dark cycle. All procedures performed on the mice
were in compliance with the guidelines approved by the
Institutional Animal Care and Use Committee (IACUC)
of Wake Forest University and the National Institutes of
Health Guide for the Care and Use of Animals.
Adoptive Transfer
For adoptive transfers, donor leukocytes were harvested
from the spleens and bone marrow of sacrificed SR/CR
mice, pooled in phosphate buffered saline and counted.
The various experimental setups used one donor mouse
per recipient with the exception of the mismatch experi-
mental setup, which used one donor per recipient for the
male donors and approximately 1.5 donors per recipient
for the female donors due to differences in the spleen
sizes. The number of leukocytes transferred to each donor
was well above the minimum number of transferred leu-
kocytes (5 × 106) that are necessary to transfer the SR/CR
phenotype (unpublished data). The number of trans-
ferred cells was matched within each experimental group
based on a cell count or approximate spleen size and
ranged from 51 × 106 to 102 × 106 or 1 to 1.5 spleens per
recipient. The exception to this range and matching crite-
ria were the cryopreservation adoptive transfer experimen-
tal group which had an approximately 2 × 106 difference
between the control and treated group (7-9 × 106 for each
recipient). The pooled donor leukocytes were then
treated, if applicable, and injected intraperitoneally (IP)
into recipient mice. One day after the leukocyte transfers,
recipient mice were challenged with 1 × 106 S180 to verify
resistance. As previously shown [2], recipient mice sur-
vived the S180 challenges only if the transfers of the SR/
CR leukocytes were successful.
Irradiation
When desired, leukocytes from donor mice were irradi-
ated in flasks with a total accumulated dose of 25 Gray
(Gy) with a cesium irradiator.
Cryopreservation
For cryopreserving, donor leukocytes were resuspended in
a cryopreserving media consisting of 90% FBS +10%
Dimethyl Sulfoxide (DMSO) and stored first in a -80°C
freezer for approximately one day before being transferred
to liquid nitrogen for approximately one month. Before
transfers, the stored leukocytes were thawed in a 37°C
water bath, washed two times with phosphate buffered
saline to remove any remaining fetal bovine serum, and
counted via trypan blue exclusion.
Histological Analysis
At desired time points of the studies, mice were sacrificed.
The lungs, livers, intestines, kidneys, spleens and other tis-
sues of potential interest were dissected and stored in 10%
neutral buffered formalin. The collected tissues were
embedded in paraffin. Sections of the tissues were stained
with hematoxylin and eosin and examined for histologi-
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